Immune response results of vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase II trial in patients with non-muscle invasive bladder cancer (NMIBC).
暂无分享，去创建一个
K. Chamie | G. Steinberg | A. Kamat | W. Walsh | T. Bivalacqua | J. Holzbeierlein | R. Grubb | E. Trabulsi | N. Shore | T. Schreiber | Michael Williams | J. Bailen | L. Karsh | M. Woods | W. Harb | J. Cochran | M. Price | R. David | F. Wolk | B. Early